We propose to establish a multidisciplinary team of epidemiologists, statisticians, basic scientists and clinician scientists to promote and pursue thorough identification and characterization of genomic loci associated with prostate cancer. ELLIPSE (ELucidating Loci Involved in Prostate cancer SuscEptibility) is a translational grant comprised of three highly integrated projects. Project 1 aims to take advantage of existing and shortly to be completed GWAS of prostate cancer in European, African American, Latino and Japanese populations to discover novel risk loci, and to rigorously replicate these associations in large existing consortia of prostate cases and controls (PRACTICAL, BPC3, and MADCaP). A major focus of this expanded effort is to identify loci that may selectively be associated with advanced disease and variants that contribute to ethnic difference in disease risk. Selective fine mapping of risk loci will also be performed to comprehensively characterize the relevant allelic locus, utilizing all available data on common variants from Hapmap, selective sequencing efforts, and from the 1000 Genome Project. Project 2 is focused on understanding the gene(s) that the non-protein coding risk variants are acting through. Two hypotheses will be systematically explored using a wide variety of established and emerging techniques: the risk loci harbor as yet undetected transcripts (either coding or non-coding) and the risk loci are regulatory elements. Finally, in Project 3 we propose to investigate the potential of this new knowledge on the genetic basis of prostate cancer susceptibility to enhance risk assessment, through gene-gene and gene-environment interactions, and importantly, to provide the potential for novel clinical practices through impacts on cancer diagnosis and treatment, or newer cancer prevention strategies. The overarching goal is to discover the pathways that drive prostate cancer pathogenesis and to assess their role in clinical decision making.
The discovery of novel risk alleles for prostate cancer will provide new insights into biological pathways that are important in the development of prostate cancer, particularly aggressive disease. This insight into prostate cancer biology will disclose novel targets for chemopreventive and therapeutic interventions and may reveal approaches to primary prevention.
|Sud, Amit; Thomsen, Hauke; Orlando, Giulia et al. (2018) Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. Blood 132:2040-2052|
|Zuber, Verena; Jönsson, Erik G; Frei, Oleksandr et al. (2018) Identification of shared genetic variants between schizophrenia and lung cancer. Sci Rep 8:674|
|Park, Sungshim L; Cheng, Iona; Haiman, Christopher A (2018) Genome-Wide Association Studies of Cancer in Diverse Populations. Cancer Epidemiol Biomarkers Prev 27:405-417|
|O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166|
|Rebbeck, Timothy R (see original citation for additional authors) (2018) Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat 39:593-620|
|Went, Molly; Sud, Amit; Försti, Asta et al. (2018) Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun 9:3707|
|FitzGerald, L M; Zhao, S; Leonardson, A et al. (2018) Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis 21:228-237|
|Matejcic, Marco; Saunders, Edward J; Dadaev, Tokhir et al. (2018) Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat Commun 9:4616|
|Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987|
|Loveday, Chey; Litchfield, Kevin; Levy, Max et al. (2018) Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer. Oncotarget 9:12630-12638|
Showing the most recent 10 out of 154 publications